Metastatic Renal Cell Carcinoma

Oncology·MeSH: Carcinoma, Renal Cell

Prevalence

48.0 / 100K

Incidence

15.0 / 100K/yr

7 drugs in development·5 companies·18 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
Aybintio (SB8)	Organon & Co. (OGN)
proleukin	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Phase 3(3)

Drug	Company
avelumab	CG Oncology, Inc. (CGON)
Evolocumab	UNITED THERAPEUTICS Corp (UTHR)
rocapuldencel-t	ARGOS THERAPEUTICS INC (ARGS)

Phase 2(2)

Drug	Company
cabozantinib	CG Oncology, Inc. (CGON)
lenvatinib	CG Oncology, Inc. (CGON)

BioSniper tracks 7 drugs in development for Metastatic Renal Cell Carcinoma across 5 companies.

There are 18 clinical trials targeting Metastatic Renal Cell Carcinoma tracked by BioSniper.

The estimated prevalence of Metastatic Renal Cell Carcinoma is approximately 48.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.